Sun Pharmaceutical Industries reported a twenty percent year-on-year decline in its consolidated net profit for the first quarter of FY26, posting INR 2,278.63 crore compared to INR 2,835.62 crore in the same quarter of the previous fiscal year.

Despite the decline in profit, the company recorded a nine point five percent rise in total revenue from operations, reaching INR 13,851.4 crore, up from INR 12,652.75 crore a year earlier. This growth was driven by strong performance across key markets, according to the company.

India formulation sales rose by thirteen point nine percent to INR 4,721.2 crore, accounting for thirty-four point two percent of the total consolidated revenue. The US formulation business, a strategic focus area for Sun, grew by one point four percent to USD 473 million, contributing twenty-nine point three percent to overall revenue.

The company’s Global Innovative Medicines segment (formerly the specialty division) delivered sixteen point nine percent growth, generating USD 311 million and accounting for nineteen point three percent of the quarterly revenue. Sales in emerging markets increased five point one percent to USD 298 million, contributing eighteen point five percent, while sales in the Rest of the World (RoW) markets rose fifteen point five percent to USD 219 million, comprising thirteen point six percent of overall sales.

Sun’s investment in research and development climbed to INR 902.9 crore from INR 794 crore a year earlier, representing six point five percent of the quarterly revenue. EBITDA rose nineteen point two percent to INR 4,301.7 crore, with the EBITDA margin improving to thirty-one point one percent.

Chairman and Managing Director Dilip Shanghvi said, “Sun had a strong performance this quarter, with steady progress across all markets. India remains a key growth driver.”

He also highlighted the US launch of Leqselvi (deuruxolitinib) for severe alopecia areata as a notable milestone in the company’s dermatology and innovative medicines portfolio.

External active pharmaceutical ingredient (API) sales reached INR 540.4 crore, registering a nine point three percent growth. Sun’s clinical R&D pipeline currently includes six novel entities across oncology, dermatology, diabetes, and pain management. The company’s US portfolio remains robust with 542 approved abbreviated new drug applications (ANDAs) and 57 approved new drug applications (NDAs), along with several filings awaiting regulatory approval from the US FDA.